Anthelmintic Drugs Market

Anthelmintic Drugs Market (Drug Class: Benzimidazole, Piperazine, and Others; and Route of Administration: Oral and Injectable) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Anthelmintic Drugs Market Outlook 2031

  • The global industry was valued at US$ 2.6 Bn in 2022
  • It is expected to grow at a CAGR of 3.9% from 2023 to 2031 and reach US$ 3.7 Bn by the end of 2031

Analyst Viewpoint

Growth in incidence of helminth infections worldwide is a key factor driving the anthelmintic drugs market revenue. These drugs help expel helminths (parasitic worms) and other internal parasites from the human or animal body without causing any major harm to the host.

Increase in frequency of compound screening with parasites is expediting the discovery of anthelmintic drugs.

Anthelmintic drugs market manufacturers are using plant materials with more than 90% of egg hatching inhibitory effects as anthelmintic agents, thereby offering dose-dependent anthelmintic activities.

Key players are following the latest anthelmintic drugs market trends and introducing clinically appropriate, safe, and cost-effective anthelmintic drugs that help achieve optimal therapeutic outcomes.

Market Introduction

Anthelmintic drugs, also known as anthelmintics, are designed to fight infections caused due to parasites. These parasites, called helminths, can infect lungs, intestines, or body tissues of human beings or animals.

Anthelmintics work either by disturbing the metabolic processes of parasites or killing them. In both the methods, the ultimate objective is to drive them away from the body.

In January 2023, the WHO published an article that stated that soil-transmitted helminth (STH) infections affect more than 24% of the global population. It further stated that such infections target the impoverished and most vulnerable communities that have limited access to hygiene, sanitation, and safe water.

Rise in need for anthelmintic drugs to combat these infections is augmenting the anti-parasitic medications market.

Anthelmintics drugs are being used in various mass deworming campaigns for school-going children in several under-developed economies. They are also used for livestock mass deworming.

Thus, the deworming drugs market is expanding at a steady pace across the globe, with albendazole and mebendazole prescribed for soil-transmitted helminths, and praziquantel for tapeworms and schistosomiasis.

Veterinary anthelmintic drugs market dynamics are governed by anthelmintic drugs that are prescribed for off-label usage in veterinary medicine.

Pyrantel pamoate (brand names Nemex and Nemex 2) is one such dewormer prescribed off-label for the treatment of intestinal roundworm, stomach worm, and hookworm parasites in cats, dogs, birds, rodents, and rabbits.

Attribute Detail
Market Drivers
  • Growth in Incidence of Helminth Infections
  • Extensive Research in Anthelmintic Medications

Rise in Incidence of Helminth Infections Boosting Anthelmintic Drugs Market Size

Helminths such as trematodes, nematodes, and cestodes are a global threat worldwide, as existing medications such as diethylcarbamazine, benzimidazoles, praziquantel, and ivermectin are at the risk of developing resistance, thereby halting the progress regarding keeping helminth infections in control.

One of the goals of the WHO is to eliminate or control these tropical ailments. As per Pan American Health Organization (PAHO), countries accounting for maximum helminth infections include Colombia, Brazil, Mexico, Guatemala, Bolivia, Honduras, Haiti, Peru, Nicaragua, and the Dominican Republic.

High incidence of helminth infections in these countries can be ascribed to the lack of adequate sanitation facilities such as unkempt septic tanks and ventilated pit latrines.

Research states that one gram of nightsoil from an infected person is likely to contain close to 100 parasite eggs. This is fueling the anthelmintic drugs market growth.

The WHO/PAHO has recommended interventions such as mass administration of mebendazole (500 mg) or albendazole (400 mg) to those at a higher risk of STH infection such as pre-schoolers, school-going children, women of childbearing age, pregnant women, and lactating mothers due to the high incidence of helminth infections across the globe.

Extensive Research in Anthelmintic Medications Fostering Market Development

The WHO encourages the sharing of resources and data regarding research findings related to anthelmintic drugs in order to exercise mass control over helminth infections. For instance, open sources, including genomic information from several parasites, have facilitated identification of targets for novel anti-parasitic agents.

Phenotyping screening and compound screening are recommended to enable screening in various assays against several diverse parasitic pathogens. Out of these compounds that have been identified, tolfenpyrad, a repurposed insecticide, has been successful in creating more selective and potent derivatives.

Lymphatic filariasis (LF) treatment was one such initiative undertaken by the WHO in 2000. It resulted in the elimination of LF as a public health problem in 14 countries.

Thus, ongoing discoveries pertaining to anthelmintic drugs are augmenting the global anthelmintic drugs market.

Regional Outlook

Attribute Detail
Leading Region North America

As per the recent anthelmintic drugs market insights, North America accounted for the largest share of the global landscape in 2022. The region is expected to maintain its dominance during the forecast period.

The U.S. is one of the top anthelmintic drugs manufacturers worldwide. Growth in pharmaceuticals-related infrastructure in the country is generating lucrative anthelmintic drugs business opportunities for companies operating in the sector in North America.

Asia Pacific, Latin America, and Middle East & Africa also constitute vital anthelmintic drugs market share due to the vast presence of low-income groups who are prone to helminth infections in the wake of inadequate sanitation facilities.

Analysis of Key Players in Anthelmintic Drugs Industry

The WHO and PAHO are collaborating with key players in the anthelmintic drugs industry to mass manufacture anthelmintic drugs in order to serve the under-developed economies of Latin America, Middle East & Africa, and Asia Pacific. For instance, albendazole and mebendazole are mass produced to be administered in these regions.

Leading market players are also incorporating nemacol, a small molecule inhibitor of C. elegans vesicular acetylcholine transporter with anthelmintic potential, into their offerings of anthelmintic drugs.

Anthelmintic drugs market report scope covers prominent players such as Novartis AG, Zoetis, Inc., Amneal Pharmaceuticals, Inc., Cipla Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Sun Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Bayer AG, Merck & Co. Inc. (Intervet Inc.), and Boehringer Ingelheim International GmbH.

These companies have been summarized in the market report in terms of parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments

  • In January 2022, Zoetis received approval for a new label indication for Simparica Trio from the U.S. FDA. Simparica Trio is the first and only combination product that prevents infections that may cause Lyme disease.

Anthelmintic Drugs Market Snapshot

Attribute Detail
Market Size in 2022 US$ 2.6 Bn
Market Forecast (Value) in 2031 US$ 3.7 Bn
Growth Rate (CAGR) 3.9%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Drug Class
    • Benzimidazole
    • Piperazine
    • Others
  • Route of Administration
    • Oral
    • Injectable
  • Application
    • Human
      • Parenchymal Neurocysticercosis
      • Gastrointestinal Infections
    • Animal
  • Target Pathogen
    • Ascaris Lumbricoides (Roundworm)
    • Trichuris Trichiura (Whipworm)
    • Enterobius Vermicularis (Pinworm)
    • Ancylostoma Duodenale (Hookworm)
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Veterinary Pharmacies
    • Veterinary Hospitals & Clinics
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC
Companies Profiled
  • Novartis AG
  • Zoetis, Inc.
  • Amneal Pharmaceuticals, Inc.
  • Cipla Inc.
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  • Sun Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Bayer AG
  • Merck & Co. Inc. (Intervet Inc.)
  • Boehringer Ingelheim International GmbH
Customization Scope Available Upon Request
Pricing Available Upon Request

Frequently Asked Questions

How big was the global anthelmintic drugs market in 2022?

It was valued at US$ 2.6 Bn in 2022

How is the anthelmintic drugs business expected to grow during the forecast period?

It is projected to grow at a CAGR of 3.9% from 2023 to 2031

What are the key factors driving the demand for anthelmintic drugs?

Growth in incidence of helminth infection and extensive research in anthelmintic medications

Which anthelmintic drugs distribution channel segment held the largest share in 2022?

The hospital pharmacies segment accounted for the largest share in 2022

Which region dominated the global anthelmintic drugs landscape in 2022?

North America was the dominant region in 2022

Who are the key anthelmintic drugs manufacturers?

Novartis AG, Zoetis, Inc., Amneal Pharmaceuticals, Inc., Cipla Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Sun Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Bayer AG, Merck & Co. Inc. (Intervet Inc.), and Boehringer Ingelheim International GmbH

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Anthelmintic Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Anthelmintic Drugs Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Anthelmintic Drugs Market Analysis and Forecast, by Drug Class

        6.1. Introduction and Definitions

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Drug Class, 2017–2031

            6.3.1. Benzimidazole

            6.3.2. Piperazine

            6.3.3. Others

        6.4. Market Attractiveness, by Drug Class

    7. Global Anthelmintic Drugs Market Analysis and Forecast, by Route of Administration

        7.1. Introduction and Definitions

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Route of Administration, 2017–2031

            7.3.1. Oral

            7.3.2. Injectable

        7.4. Market Attractiveness, by Route of Administration

    8. Global Anthelmintic Drugs Market Analysis and Forecast, By Application

        8.1. Introduction and Definitions

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, By Application, 2017–2031

            8.3.1. Human

                8.3.1.1. Parenchymal Neurocysticercosis

                8.3.1.2. Gastrointestinal Infections

            8.3.2. Animal

        8.4. Market Attractiveness, By Application

    9. Global Anthelmintic Drugs Market Analysis and Forecast, by Target Pathogen

        9.1. Introduction and Definitions

        9.2. Key Findings/Developments

        9.3. Market Value Forecast, by Target Pathogen, 2017–2031

            9.3.1. Ascaris Lumbricoides (Roundworm)

            9.3.2. Trichuris Trichiura (Whipworm)

            9.3.3. Enterobius Vermicularis (Pinworm)

            9.3.4. Ancylostoma Duodenale (Hookworm)

            9.3.5. Others

        9.4. Market Attractiveness, by Target Pathogen

    10. Global Anthelmintic Drugs Market Analysis and Forecast, by Distribution Channel

        10.1. Introduction and Definitions

        10.2. Key Findings/Developments

        10.3. Market Value Forecast, by Distribution Channel, 2017–2031

            10.3.1. Hospital Pharmacies

            10.3.2. Retail Pharmacies

            10.3.3. Online Pharmacies

            10.3.4. Veterinary Pharmacies

            10.3.5. Veterinary Hospitals & Clinics

        10.4. Market Attractiveness, by Distribution Channel

    11. Global Anthelmintic Drugs Market Analysis and Forecast, by Region

        11.1. Key Findings

        11.2. Market Value Forecast, by Region, 2017–2031

            11.2.1. North America

            11.2.2. Europe

            11.2.3. Asia Pacific

            11.2.4. Latin America

            11.2.5. Middle East & Africa

        11.3. Market Attractiveness, by Region

    12. North America Anthelmintic Drugs Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Drug Class, 2017–2031

            12.2.1. Benzimidazole

            12.2.2. Piperazine

            12.2.3. Others

        12.3. Market Attractiveness, by Drug Class

        12.4. Market Value Forecast, by Route of Administration, 2017–2031

            12.4.1. Oral

            12.4.2. Injectable

        12.5. Market Attractiveness, by Route of Administration

        12.6. Market Value Forecast, By Application, 2017–2031

            12.6.1. Human

                12.6.1.1. Parenchymal Neurocysticercosis

                12.6.1.2. Gastrointestinal Infections

            12.6.2. Animal

        12.7. Market Attractiveness, By Application

        12.8. Market Value Forecast, by Target Pathogen, 2017–2031

            12.8.1. Ascaris Lumbricoides (Roundworm)

            12.8.2. Trichuris Trichiura (Whipworm)

            12.8.3. Enterobius Vermicularis (Pinworm)

            12.8.4. Ancylostoma Duodenale (Hookworm)

            12.8.5. Others

        12.9. Market Attractiveness, by Target Pathogen

        12.10. Market Value Forecast, by Distribution Channel, 2017–2031

            12.10.1. Hospital Pharmacies

            12.10.2. Retail Pharmacies

            12.10.3. Online Pharmacies

            12.10.4. Veterinary Pharmacies

            12.10.5. Veterinary Hospitals & Clinics

        12.11. Market Attractiveness, by Distribution Channel

        12.12. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.12.1. U.S.

            12.12.2. Canada

        12.13. Market Attractiveness Analysis

            12.13.1. By Drug Class

            12.13.2. By Route of Administration

            12.13.3. By Application

            12.13.4. By Target Pathogen

            12.13.5. By Distribution Channel

            12.13.6. By Country

    13. Europe Anthelmintic Drugs Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Drug Class, 2017–2031

            13.2.1. Benzimidazole

            13.2.2. Piperazine

            13.2.3. Others

        13.3. Market Attractiveness, by Drug Class

        13.4. Market Value Forecast, by Route of Administration, 2017–2031

            13.4.1. Oral

            13.4.2. Injectable

        13.5. Market Attractiveness, by Route of Administration

        13.6. Market Value Forecast, By Application, 2017–2031

            13.6.1. Human

                13.6.1.1. Parenchymal Neurocysticercosis

                13.6.1.2. Gastrointestinal Infections

            13.6.2. Animal

        13.7. Market Attractiveness, By Application

        13.8. Market Value Forecast, by Target Pathogen, 2017–2031

            13.8.1. Ascaris Lumbricoides (Roundworm)

            13.8.2. Trichuris Trichiura (Whipworm)

            13.8.3. Enterobius Vermicularis (Pinworm)

            13.8.4. Ancylostoma Duodenale (Hookworm)

            13.8.5. Others

        13.9. Market Attractiveness, by Target Pathogen

        13.10. Market Value Forecast, by Distribution Channel, 2017–2031

            13.10.1. Hospital Pharmacies

            13.10.2. Retail Pharmacies

            13.10.3. Online Pharmacies

            13.10.4. Veterinary Pharmacies

            13.10.5. Veterinary Hospitals & Clinics

        13.11. Market Attractiveness, by Distribution Channel

        13.12. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.12.1. Germany

            13.12.2. U.K.

            13.12.3. France

            13.12.4. Italy

            13.12.5. Spain

            13.12.6. Rest of Europe

        13.13. Market Attractiveness Analysis

            13.13.1. By Drug Class

            13.13.2. By Route of Administration

            13.13.3. By Application

            13.13.4. By Target Pathogen

            13.13.5. By Distribution Channel

            13.13.6. By Country/Sub-region

    14. Asia Pacific Anthelmintic Drugs Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Drug Class, 2017–2031

            14.2.1. Benzimidazole

            14.2.2. Piperazine

            14.2.3. Others

        14.3. Market Attractiveness, by Drug Class

        14.4. Market Value Forecast, by Route of Administration, 2017–2031

            14.4.1. Oral

            14.4.2. Injectable

        14.5. Market Attractiveness, by Route of Administration

        14.6. Market Value Forecast, By Application, 2017–2031

            14.6.1. Human

                14.6.1.1. Parenchymal Neurocysticercosis

                14.6.1.2. Gastrointestinal Infections

            14.6.2. Animal

        14.7. Market Attractiveness, By Application

        14.8. Market Value Forecast, by Target Pathogen, 2017–2031

            14.8.1. Ascaris Lumbricoides (Roundworm)

            14.8.2. Trichuris Trichiura (Whipworm)

            14.8.3. Enterobius Vermicularis (Pinworm)

            14.8.4. Ancylostoma Duodenale (Hookworm)

            14.8.5. Others

        14.9. Market Attractiveness, by Target Pathogen

        14.10. Market Value Forecast, by Distribution Channel, 2017–2031

            14.10.1. Hospital Pharmacies

            14.10.2. Retail Pharmacies

            14.10.3. Online Pharmacies

            14.10.4. Veterinary Pharmacies

            14.10.5. Veterinary Hospitals & Clinics

        14.11. Market Attractiveness, by Distribution Channel

        14.12. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.12.1. China

            14.12.2. Japan

            14.12.3. India

            14.12.4. Australia & New Zealand

            14.12.5. Rest of Asia Pacific

        14.13. Market Attractiveness Analysis

            14.13.1. By Drug Class

            14.13.2. By Route of Administration

            14.13.3. By Application

            14.13.4. By Target Pathogen

            14.13.5. By Distribution Channel

            14.13.6. By Country/Sub-region

    15. Latin America Anthelmintic Drugs Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Drug Class, 2017–2031

            15.2.1. Benzimidazole

            15.2.2. Piperazine

            15.2.3. Others

        15.3. Market Attractiveness, by Drug Class

        15.4. Market Value Forecast, by Route of Administration, 2017–2031

            15.4.1. Oral

            15.4.2. Injectable

        15.5. Market Attractiveness, by Route of Administration

        15.6. Market Value Forecast, By Application, 2017–2031

            15.6.1. Human

                15.6.1.1. Parenchymal Neurocysticercosis

                15.6.1.2. Gastrointestinal Infections

            15.6.2. Animal

        15.7. Market Attractiveness, By Application

        15.8. Market Value Forecast, by Target Pathogen, 2017–2031

            15.8.1. Ascaris Lumbricoides (Roundworm)

            15.8.2. Trichuris Trichiura (Whipworm)

            15.8.3. Enterobius Vermicularis (Pinworm)

            15.8.4. Ancylostoma Duodenale (Hookworm)

            15.8.5. Others

        15.9. Market Attractiveness, by Target Pathogen

        15.10. Market Value Forecast, by Distribution Channel, 2017–2031

            15.10.1. Hospital Pharmacies

            15.10.2. Retail Pharmacies

            15.10.3. Online Pharmacies

            15.10.4. Veterinary Pharmacies

            15.10.5. Veterinary Hospitals & Clinics

        15.11. Market Attractiveness, by Distribution Channel

        15.12. Market Value Forecast, by Country/Sub-region, 2017–2031

            15.12.1. Brazil

            15.12.2. Mexico

            15.12.3. Rest of Latin America

        15.13. Market Attractiveness Analysis

            15.13.1. By Drug Class

            15.13.2. By Route of Administration

            15.13.3. By Application

            15.13.4. By Target Pathogen

            15.13.5. By Distribution Channel

            15.13.6. By Country/Sub-region

    16. Middle East & Africa Anthelmintic Drugs Market Analysis and Forecast

        16.1. Introduction

            16.1.1. Key Findings

        16.2. Market Value Forecast, by Drug Class, 2017–2031

            16.2.1. Benzimidazole

            16.2.2. Piperazine

            16.2.3. Others

        16.3. Market Attractiveness, by Drug Class

        16.4. Market Value Forecast, by Route of Administration, 2017–2031

            16.4.1. Oral

            16.4.2. Injectable

        16.5. Market Attractiveness, by Route of Administration

        16.6. Market Value Forecast, By Application, 2017–2031

            16.6.1. Human

                16.6.1.1. Parenchymal Neurocysticercosis

                16.6.1.2. Gastrointestinal Infections

            16.6.2. Animal

        16.7. Market Attractiveness, By Application

        16.8. Market Value Forecast, by Target Pathogen, 2017–2031

            16.8.1. Ascaris Lumbricoides (Roundworm)

            16.8.2. Trichuris Trichiura (Whipworm)

            16.8.3. Enterobius Vermicularis (Pinworm)

            16.8.4. Ancylostoma Duodenale (Hookworm)

            16.8.5. Others

        16.9. Market Attractiveness, by Target Pathogen

        16.10. Market Value Forecast, by Distribution Channel, 2017–2031

            16.10.1. Hospital Pharmacies

            16.10.2. Retail Pharmacies

            16.10.3. Online Pharmacies

            16.10.4. Veterinary Pharmacies

            16.10.5. Veterinary Hospitals & Clinics

        16.11. Market Attractiveness, by Distribution Channel

        16.12. Market Value Forecast, by Country/Sub-region, 2017–2031

            16.12.1. GCC Countries

            16.12.2. South Africa

            16.12.3. Rest of Middle East & Africa

        16.13. Market Attractiveness Analysis

            16.13.1. By Drug Class

            16.13.2. By Route of Administration

            16.13.3. By Application

            16.13.4. By Target Pathogen

            16.13.5. By Distribution Channel

            16.13.6. By Country/Sub-region

    17. Competition Landscape

        17.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        17.2. Market Share Analysis, by Company (2022)

        17.3. Company Profiles

            17.3.1. Novartis AG

                17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.1.2. Product Portfolio

                17.3.1.3. Financial Overview

                17.3.1.4. SWOT Analysis

                17.3.1.5. Strategic Overview

            17.3.2. Zoetis, Inc.

                17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.2.2. Product Portfolio

                17.3.2.3. Financial Overview

                17.3.2.4. SWOT Analysis

                17.3.2.5. Strategic Overview

            17.3.3. Amneal Pharmaceuticals, Inc.

                17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.3.2. Product Portfolio

                17.3.3.3. Financial Overview

                17.3.3.4. SWOT Analysis

                17.3.3.5. Strategic Overview

            17.3.4. Cipla Inc.

                17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.4.2. Product Portfolio

                17.3.4.3. Financial Overview

                17.3.4.4. SWOT Analysis

                17.3.4.5. Strategic Overview

            17.3.5. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

                17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.5.2. Product Portfolio

                17.3.5.3. Financial Overview

                17.3.5.4. SWOT Analysis

                17.3.5.5. Strategic Overview

            17.3.6. Sun Pharmaceutical Industries Ltd.

                17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.6.2. Product Portfolio

                17.3.6.3. Financial Overview

                17.3.6.4. SWOT Analysis

                17.3.6.5. Strategic Overview

            17.3.7. GlaxoSmithKline plc

                17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.7.2. Product Portfolio

                17.3.7.3. Financial Overview

                17.3.7.4. SWOT Analysis

                17.3.7.5. Strategic Overview

            17.3.8. Bayer AG

                17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.8.2. Product Portfolio

                17.3.8.3. Financial Overview

                17.3.8.4. SWOT Analysis

                17.3.8.5. Strategic Overview

            17.3.9. Merck & Co. Inc. (Intervet Inc.)

                17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.9.2. Product Portfolio

                17.3.9.3. Financial Overview

                17.3.9.4. SWOT Analysis

                17.3.9.5. Strategic Overview

            17.3.10. Boehringer Ingelheim International GmbH

                17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.10.2. Product Portfolio

                17.3.10.3. Financial Overview

                17.3.10.4. SWOT Analysis

                17.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 02: Global Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 03: Global Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Target Pathogen, 2017–2031

    Table 04: Global Anthelmintic Drugs Market Size (US$ Mn) Forecast, By Application, 2017–2031

    Table 05: Global Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 06: Global Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2031

    Table 07: North America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2031

    Table 08: North America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 09: North America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 10: North America Anthelmintic Drugs Market Size (US$ Mn) Forecast, By Application, 2017–2031

    Table 11: North America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Target Pathogen, 2017–2031

    Table 12: North America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Europe Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Europe Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 15: Europe Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 16: Europe Anthelmintic Drugs Market Size (US$ Mn) Forecast, By Application, 2017–2031

    Table 17: Europe Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Target Pathogen, 2017–2031

    Table 18: Europe Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 19: Asia Pacific Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 20: Asia Pacific Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 21: Asia Pacific Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 22: Asia Pacific Anthelmintic Drugs Market Size (US$ Mn) Forecast, By Application, 2017–2031

    Table 23: Asia Pacific Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Target Pathogen, 2017–2031

    Table 24: Asia Pacific Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 25: Latin America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 26: Latin America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 27: Latin America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 28: Latin America Anthelmintic Drugs Market Size (US$ Mn) Forecast, By Application, 2017–2031

    Table 29: Latin America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Target Pathogen, 2017–2031

    Table 30: Latin America Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 31: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 32: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 33: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 34: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast, By Application, 2017–2031

    Table 35: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Target Pathogen, 2017–2031

    Table 36: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Anthelmintic Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031

    Figure 02: Global Anthelmintic Drugs Market Revenue (US$ Mn), by Drug Class, 2022

    Figure 03: Global Anthelmintic Drugs Market Value Share, by Drug Class, 2022

    Figure 04: Global Anthelmintic Drugs Market Revenue (US$ Mn), by Route of Administration, 2022

    Figure 05: Global Anthelmintic Drugs Market Value Share, by Route of Administration, 2022

    Figure 06: Global Anthelmintic Drugs Market Revenue (US$ Mn), By Application, 2022

    Figure 07: Global Anthelmintic Drugs Market Value Share, By Application, 2022

    Figure 08: Global Anthelmintic Drugs Market Revenue (US$ Mn), by Target Pathogen, 2022

    Figure 09: Global Anthelmintic Drugs Market Value Share, by Target Pathogen, 2022

    Figure 10: Global Anthelmintic Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022

    Figure 11: Global Anthelmintic Drugs Market Value Share, by Distribution Channel, 2022

    Figure 12: Global Anthelmintic Drugs Market Value Share, by Region, 2022

    Figure 13: Global Anthelmintic Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 14: Global Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 15: Global Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 16: Global Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

    Figure 17: Global Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

    Figure 18: Global Anthelmintic Drugs Market Value Share Analysis, By Application, 2022–2031

    Figure 19: Global Anthelmintic Drugs Market Attractiveness Analysis, By Application, 2023–2031

    Figure 20: Global Anthelmintic Drugs Market Revenue (US$ Mn), by Target Pathogen, 2022

    Figure 21: Global Anthelmintic Drugs Market Value Share, by Target Pathogen, 2022

    Figure 22: Global Anthelmintic Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022

    Figure 23: Global Anthelmintic Drugs Market Value Share, by Distribution Channel, 2022

    Figure 24: Global Anthelmintic Drugs Market Value Share Analysis, by Region, 2022–2031

    Figure 25: Global Anthelmintic Drugs Market Attractiveness Analysis, by Region, 2023–2031

    Figure 26: North America Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 27: North America Anthelmintic Drugs Market Attractiveness Analysis, by Country, 2023–2031

    Figure 28: North America Anthelmintic Drugs Market Value Share Analysis, by Country, 2022–2031

    Figure 29: North America Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 30: North America Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

    Figure 31: North America Anthelmintic Drugs Market Value Share Analysis, By Application, 2022–2031

    Figure 32: North America Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2022–2031

    Figure 33: North America Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 34: North America Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 35: North America Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

    Figure 36: North America Anthelmintic Drugs Market Attractiveness Analysis, By Application, 2023–2031

    Figure 37: North America Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2023–2031

    Figure 38: North America Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 39: Europe Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 40: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 41: Europe Anthelmintic Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 42: Europe Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 43: Europe Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

    Figure 44: Europe Anthelmintic Drugs Market Value Share Analysis, By Application, 2022–2031

    Figure 45: Europe Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2022–2031

    Figure 46: Europe Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 47: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 48: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

    Figure 49: Europe Anthelmintic Drugs Market Attractiveness Analysis, By Application, 2023–2031

    Figure 50: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2023–2031

    Figure 51: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 52: Asia Pacific Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 53: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 54: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 55: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 56: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

    Figure 57: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, By Application, 2022–2031

    Figure 58: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2022–2031

    Figure 59: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 60: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 61: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

    Figure 62: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, By Application, 2023–2031

    Figure 63: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2023–2031

    Figure 64: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 65: Latin America Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 66: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 67: Latin America Anthelmintic Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 68: Latin America Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 69: Latin America Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

    Figure 70: Latin America Anthelmintic Drugs Market Value Share Analysis, By Application, 2022–2031

    Figure 71: Latin America Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2022–2031

    Figure 72: Latin America Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 73: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 74: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

    Figure 75: Latin America Anthelmintic Drugs Market Attractiveness Analysis, By Application, 2023–2031

    Figure 76: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2023–2031

    Figure 77: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 78: Middle East & Africa Anthelmintic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 79: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 80: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 81: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 82: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2022–2031

    Figure 83: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, By Application, 2022–2031

    Figure 84: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2022–2031

    Figure 85: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 86: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 87: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2023–2031

    Figure 88: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, By Application, 2023–2031

    Figure 89: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2023–2031

    Figure 90: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved